Rybrevant Faspro shrank tumours in 42% of patients, but can Johnson & Johnson prove survival benefit?
FDA approves Rybrevant Faspro for selected advanced head and neck cancers after a 42% response rate. Survival evidence remains the next test.
Pharma & Biotech